The search for safe compounds, robust assays and better drug delivery systems for improved anticancer activity

Molecular Biomarkers & Diagnosis

ISSN: 2155-9929

Open Access

The search for safe compounds, robust assays and better drug delivery systems for improved anticancer activity

2nd World Congress on Biomarkers & Clinical Research

12-14 September 2011 Baltimore, USA

Crispin R. Dass

Scientific Tracks Abstracts: J Mol Biomark Diagn

Abstract :

Cancer is a group of diseases characterized by uncontrolled growth of cells in the body. Th ese lesions, if not treated, grow until they become life-threatening or fatal. Traditionally, surgery has been the main form of tumor control, though this is not performed where the growth is deep-seated in the body or located at a site where surgery could itself be life-threatening. Alternatives to, or assisting surgery are chemotherapy and radiotherapy. However, these two traditional forms of cancer therapy suff er due to harmful eff ects to the healthy parts of the body. To address this, there is a global push to fi nd compounds that are eff ective against neoplastic cells, but less harmful against normal healthy cells of the body. Complementing this is the search for in vitro or in vivo assays that are more indicative of antitumor activity. Finally, there has been a growing push to fi nd better drug delivery systems capable of more selective delivery of drugs to tumors in the body. Th is presentation discusses some of the cell-based assays and small animal models set up by our labs in the past decade, drug delivery systems we have tested so far, and biologicals (protein, nucleic acid, polysaccharide) trialed so far, some of which are undergoing clinical testing

Biography :

Crispin R. Dass has 17 years of cell and molecular biology research experience, mainly focusing on oncological R&D. His research is on systems at various levels ? in silico, in vitro, in vivo, ADME/Tox, clinical, and also with biomedical education. He has worked on projects for Johnson & Johnson, GlaxoSmithKline, Amgen, and Novartis. His extensive experience is documented in his 120 papers to date, with publications in Nature Medicine, Journal of the National Cancer Institute, Biomaterials, Nucleic Acids Research, Cancer, and Journal of Controlled Release. He is currently on the editorial board of 3 other journals in his fi eld, and has been invited to chair sessions and to give plenary lectures at national and international conferences. Based currently in St Albans (Melbourne, Australia), he has research links with Thailand, Fiji, USA, China, South Korea, Japan, Iran and India.

Google Scholar citation report
Citations: 2054

Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report

Molecular Biomarkers & Diagnosis peer review process verified at publons

Indexed In

arrow_upward arrow_upward